Skip to content

DE · SRT3.DE · MEDICAL - INSTRUMENTS & SUPPLIES

Sartorius AG (SRT3.DE) intrinsic value and stock valuation

$288.00as of 2026-11-21 · Mkt cap 15.96B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Sartorius AG DCF and intrinsic value

InvestorsCraft values SRT3.DE with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from SRT3.DE’s statements →

Sartorius AG Graham Number

Graham Number: $53.17d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Instruments & Supplies Göttingen 37079 sartorius.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$3.54B+8.7% 5y CAGRd
20112025
Net income
$154.9M-13.6% 5y CAGRd
20112025
Free cash flow
$214.1M-4.6% 5y CAGRd
20112025
Total equity
$3.87B+22.5% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$3.54B$3.38B$3.4B$4.17B$3.45B
Operating income$651.4M$437.2M$543.2M$1.14B$735.8M
Net income$154.9M$84M$205.2M$913.1M$427M
EPSd$2.24M$1.22M$3M$13.3M$6.24M
Operating cash flow$656M$976.2M$853.6M$734.2M$865.8M
Capital expenditure-$-441.9M-$-409.9M-$-559.7M-$-522.6M-$-407.17M
Free cash flow$214.1M$566.3M$293.9M$211.6M$458.7M
Total assets$9.72B$10.1B$9.76B$6.98B$5.7B
Total debt$4.45B$4.56B$5.31B$2.54B$2.08B
Net debt$3.91B$3.75B$4.93B$2.38B$1.73B
Total equity$3.87B$3.9B$2.76B$2.66B$1.72B
Cash and short-term investments$541.4M$828.7M$394.2M$196.8M$361M
Income statement
20252024202320222021
Revenue$3.54B$3.38B$3.4B$4.17B$3.45B
Cost of revenue$1.9B$1.86B$1.83B$1.98B$1.61B
Gross profit$1.64B$1.52B$1.57B$2.2B$1.84B
Research and development expenses$174M$196.8M$170.8M$177.8M$139.9M
Selling, general and administrative expenses$811.4M$884M$848.7M$829M$745.7M
Other expenses$0.00$6.4M$4.4M$13.5M$20M
Operating expenses$985.4M$1.09B$1.02B$1.02B$905.6M
Cost and expenses$2.89B$2.94B$2.85B$3B$2.52B
Interest income$13.9M$22.1M$4.6M$1M$400K
Interest expense$198M$205.4M$156.9M$67.9M$45.5M
Depreciation and amortization$420.1M$415.9M$341.6M$287.1M$231.2M
Ebitda$1.07B$786.8M$873.1M$1.5B$945.1M
Operating income$651.4M$437.2M$543.2M$1.14B$735.8M
Total other income/expenses, net-$-314.4M$0.00-$-157.2M$42.4M-$-67.4M
Income before tax$337M$186.8M$386M$1.18B$668.4M
Income tax expense$106.6M$49.4M$95.9M$268.6M$241.4M
Net income$154.9M$84M$205.2M$913.1M$427M
Weighted average shares outstanding$69.1M$69M$68.4M$68.4M$68.4M
Weighted average diluted shares outstanding$69.1M$69M$68.4M$68.4M$68.4M
Balance sheet
20252024202320222021
Cash and short-term investments$541.4M$828.7M$394.2M$196.8M$361M
Net receivables$291.7M$328.7M$350.6M$492.9M$429.3M
Inventory$792.2M$788.5M$1.04B$1.18B$874.1M
Total current assets$1.77B$2.11B$1.96B$2.02B$1.8B
Property, plant and equipment, net$2.46B$2.35B$2.08B$1.71B$1.31B
Goodwill and intangible assets$5.3B$5.47B$5.51B$3B$2.46B
Long-term investments$67.9M$66.8M$114.8M$120M$42.7M
Total non-current assets$7.95B$7.99B$7.8B$4.95B$3.9B
Total assets$9.72B$10.1B$9.76B$6.98B$5.7B
Accounts payable$343.1M$344.1M$306.5M$551.9M$515M
Short-term debt$926.4M$393.1M$288M$555M$337.4M
Deferred revenue$201.9M$0.00$0.00$0.00$614.5M
Total current liabilities$1.97B$1.44B$1.33B$1.8B$1.55B
Long-term debt$3.53B$4.17B$5.02B$1.99B$1.74B
Deferred revenue, non-current$0.00$0.00-$-200K$0.00$0.00
Total non-current liabilities$3.88B$4.76B$5.66B$2.52B$2.43B
Capital lease obligations$171.8M$181.2M$147.2M$143.6M$115M
Total liabilities$5.85B$6.21B$7B$4.32B$3.98B
Common stock$69.1M$69M$68.4M$68.4M$68.4M
Retained earnings$2.49B$2.39B$1.97B$1.83B$1.17B
Accumulated other comprehensive income (loss)-$-100.3M$63.9M-$-18.3M$50.2M-$-17.44M
Total equity$3.87B$3.9B$2.76B$2.66B$1.72B
Total investments$67.9M$82.1M$129.8M$150.9M$60.9M
Total debt$4.45B$4.56B$5.31B$2.54B$2.08B
Net debt$3.91B$3.75B$4.93B$2.38B$1.73B
Cash flow statement
20252024202320222021
Net income$154.9M$186.8M$338.5M$1.18B$668.4M
Depreciation and amortization$420.1M$415.9M$342.3M$287.1M$231.2M
Stock-based compensation$0.00$0.00$600K$1M$3.1M
Change in working capital$4.1M$277.5M$144.1M-$-389.5M-$-82.23M
Accounts receivable$45.8M$27.3M$168.6M-$-86.6M-$-99.14M
Inventory-$-48.6M$258.6M$118.1M-$-261.6M-$-294.41M
Accounts payable$0.00$0.00$0.00$86.6M$99.1M
Net cash provided by operating activities$656M$976.2M$853.6M$734.2M$865.8M
Investments in property, plant and equipment-$-441.9M-$-409.9M-$-559.7M-$-522.6M-$-407.17M
Acquisitions, net-$-66.9M$0.00-$-2.24B-$-536.1M-$-141.67M
Net cash used for investing activities-$-513.5M-$-425.8M-$-2.82B-$-1.13B-$-569.61M
Common stock issued$0.00$198.3M$0.00$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid-$-50.7M-$-50.7M-$-98.2M-$-85.9M-$-48.23M
Net cash used for financing activities-$-410.6M-$-128.3M$2.17B$209.9M-$-165.18M
Net change in cash-$-272M$434.2M$213.3M-$-176.9M$139.4M
Cash at end of period$541.4M$813.4M$379.2M$165.9M$342.8M
Operating cash flow$656M$976.2M$853.6M$734.2M$865.8M
Capital expenditure-$-441.9M-$-409.9M-$-559.7M-$-522.6M-$-407.17M
Free cash flow$214.1M$566.3M$293.9M$211.6M$458.7M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Sartorius AG

        Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services worldwide. The company offers biosensors and kits, compliance tools, systems software, label-free detection systems, and SPR systems; live-cell analysis systems, flow cytometry platform, and cell analysis reagents and consumables; and antibody and recombinant protein media, viral vaccines media, regenerative medicine media, general media, downstream buffer, microcarrier, and stem cell media and reagent products, as well as strong acids, bases, and alcohols and detergents. It also provides multi-parallel bioreactors, benchtop bioreactors, single-use bioreactors, stainless steel bioreactors, cell culture bioreactors, microbial bioreactors, and software apps for bioreactors; membranes, blotting products, filter papers, glass and quartz microfibre products, and filtration equipment; syringe filters; and filtration devices, ultrafiltration devices, sterile filtration devices, harvesting devices, analytical sample prep systems, buffer exchange systems, diagnostic sample prep systems, particle analysis systems, pharmaceutical filtration systems, protein DNA concentration systems, venting moisture barriers, clarification systems, buffer and media products, and membrane chromatography products. In addition, the company offers process filtration products; process filtration products; process chromatography products; fluid management products; process analytical technology and data analytics; industrial microbiology systems; water purification systems; weighing systems; pipetting and dispensing systems; OEM systems; and centrifuges. Further, it provides bioprocess development and engineering, protein expression system, media and process, testing, instrument, and validation services. It serves the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industries. The company was founded in 1870 and is headquartered in Göttingen, Germany.

        CEO
        Michael Grosse
        Employees
        13.57K
        Beta
        1.40

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Sartorius AG (SRT3.DE)?

        InvestorsCraft does not currently publish an intrinsic value for SRT3.DE. How the IC value is calculated.

        Is SRT3.DE undervalued?

        InvestorsCraft does not publish an undervaluation signal for SRT3.DE at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.